CFM
TBPH icon

Catalyst Funds Management’s Theravance Biopharma TBPH Stock Holding History

Catalyst Funds Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,410
Closed -$102K – 1583
2024
Q1 		$102K Buy
+11,410
New +$106K 0.03% 389

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Catalyst Funds Management's TBPH Position: Q2 2024 in Review

Catalyst Funds Management sold out of Theravance Biopharma (TBPH) in Q2 2024, closing a stake of 11,410 shares — an estimated $102K sold.

Catalyst Funds Management first reported a position in TBPH in Q1 2024 and held it in 1 quarter. The position peaked at $102K in Q1 2024. 132 funds tracked by Wall St. Rank hold TBPH as of Q2 2024.

  • Catalyst Funds Management reported no remaining Theravance Biopharma position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 11,410 Theravance Biopharma shares in Q2 2024, an estimated $102K.
  • Catalyst Funds Management first reported a position in Theravance Biopharma in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Theravance Biopharma position peaked at $102K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.